Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy

A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.

Artificial Intelligence Brexit Business Strategies

Latest From Pricing Debate

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Europe United Kingdom

Drug Pricing Among Range Of Issues Senators Want HHS Nominee Becerra To Work On

Senate Finance confirmation hearing concluded without a vote on Xavier Becerra’s nomination as Health and Human Services Department secretary. Republicans continued to express concerns with his background and views. But he is expected to win enough votes to clear the committee.

Pricing Debate Legislation

A New Start: President Biden Visits Pfizer

President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.

Pricing Debate Manufacturing

HHS Secretary Nominee Becerra Plans ‘Swift’ Action On Drug Pricing Reform

‘We need the pharmaceutical industry … to always feel we’ve got their back to innovate,’ Becerra tells Senate Committee. ‘But we have to ensure that we’re getting our dollars’ worth.’

Pricing Debate Legislation

Japan Pricing Environment ‘Highly Unpredictable’: PhRMA

US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.

Japan Policy

Senate Finance Drug Pricing Bill May Gain Traction As Panel’s Lead Health Staffer Joins CMS

Arielle Woronoff joins the Biden Administration after four years of steering health policy at the Senate Finance Committee, including work on the Grassley-Wyden bill.

Legislation Pricing Debate

Medicaid Rebate Reform: A Sign Of Minimal Drug Pricing Threats Or A Warning Of More To Come?

House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.

Legislation Medicaid

Reference Pricing Clauses In US COVID-19 Contracts Leave Drug Industry Vulnerable

Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.

Coronavirus COVID-19 Vaccines

As Pricing Scrutiny Turns To Physician-Administered Drugs, PhRMA Points To Supply Chain Culprits

Hospital receive an average of 2.5 times what they pay for drugs in reimbursement from commercial payers, a white paper released by the trade group reports. And consolidation has increased the leverage hospitals wield in payment negotiations.

Pricing Debate Private Payers
See All
UsernamePublicRestriction

Register